MetLife Investment Management’s Niagen Bioscience NAGE Stock Holding History

MetLife Investment Management’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$133K	Buy	30,139 +5,830	+24%	+$31.5K	﹤0.01%	2412
2025 Q4	$155K	Sell	24,309 -5,817	-19%	-$40.5K	﹤0.01%	2402
2025 Q3	$281K	Hold	30,126	–	–	﹤0.01%	2121
2025 Q2	$434K	Hold	30,126	–	–	﹤0.01%	1742
2025 Q1	$208K	Buy	30,126 +3,567	+13%	+$22.4K	﹤0.01%	2180
2024 Q4	$141K	Buy	26,559 +8,445	+47%	+$46.2K	﹤0.01%	2470
2024 Q3	$66.1K	Buy	18,114 +5,115	+39%	+$16.1K	﹤0.01%	2725
2024 Q2	$35.5K	Buy	+12,999	New	+$43.5K	﹤0.01%	2821
2021 Q4	–	Sell	-5,907	Closed	-$37K	–	2563
2021 Q3	$37K	Sell	5,907 -12,993	-69%	-$107K	﹤0.01%	2546
2021 Q2	$186K	Buy	18,900 +11,043	+141%	+$96.3K	﹤0.01%	2214
2021 Q1	$73.4K	Buy	+7,857	New	+$62.3K	﹤0.01%	2267

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MetLife Investment Management's NAGE Position: Q1 2026 in Review

MetLife Investment Management increased its Niagen Bioscience (NAGE) stake by 24% in Q1 2026, buying an estimated $31.5K and bringing the position to 30,139 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #2412.

MetLife Investment Management first reported a position in NAGE in Q1 2021 and has held it in 11 quarters since. The position peaked at $434K in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

MetLife Investment Management held 30,139 shares of Niagen Bioscience worth $133K as of Q1 2026.
MetLife Investment Management bought 5,830 Niagen Bioscience shares in Q1 2026, an estimated $31.5K.
Niagen Bioscience made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2412 holding.
MetLife Investment Management first reported a position in Niagen Bioscience in Q1 2021 and has held it in 11 quarters since.
MetLife Investment Management's Niagen Bioscience position peaked at $434K in Q2 2025.
143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.